Metformin Hydrochloride Wave Pharma

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Wave Pharma, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity.

GNH USA supplies Metformin Hydrochloride Wave Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Metformin Hydrochloride is a biguanide antidiabetic that acts on glucose metabolism in type 2 diabetes and related conditions. - Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): lowers the risk of progression to overt diabetes. - Polycystic ovary syndrome: helps reduce insulin resistance and may improve menstrual regularity.

Metformin Hydrochloride may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious metabolic disturbances.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Decreased appetite: reduced desire to eat. - Vitamin B12 deficiency: long‑term use may lower B12 levels.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening buildup of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Pancreatitis: inflammation of the pancreas. - Hypoglycemia: usually when combined with other glucose‑lowering agents.

Metformin Hydrochloride requires careful monitoring and specific safety measures before and during therapy. - Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. - Hepatic function monitoring: check liver enzymes to reduce risk of lactic acidosis. - Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Vitamin B12 monitoring: assess levels during long‑term therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - Warfarin: may require INR monitoring as metformin can affect anticoagulation control.